Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
- Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.Am J Cardiol. 2007; 99: 970-973
- Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.N Engl J Med. 2008; 359 (accessed July 24, 2008)https://doi.org/10.1056/NEJMoa0804602
- Simvastatin with or without ezetimibe in familial hypercholesterolemia.N Engl J Med. 2008; 358: 1431-1443
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet. 2005; 366 (Erratum in: Lancet 2005;366(9494):1358. Lancet 2008;371(9630):2084): 1267-1278
- Association between progression of aortic valve calcification and coronary calcification: assessment by electron beam tomography.Acad Radiol. 2005; 12: 298-304
- Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study.Arterioscler Thromb Vasc Biol. 2001; 1: 1623-1629
- Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy. Part III. Mechanistically defining the role of hyperlipidemia.J Lipid Res. 2005; 46: 2037-2051
- After ENHANCE, the lipid hypothesis is alive and well.Med J Aust. 2008; 189: 303
- Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.J Am Coll Cardiol. 2008; 51: 37-45
- Analyses of cancer data from three ezetimibe trials.N Engl J Med. 2008; 359: 1357-1366
Stein EA. After ENHANCE–is more LDL cholesterol lowering still better? Clin Chem 2008, April 10; published as doi:10.1373/clinchem.2008.104893 (accessed August 2, 2008).
IMPROVE-IT Trial. http://clinicaltrials.gov/ct2/show/NCT00202878?term=IMPROVE-IT&rank=1 (accessed August 2, 2008).
- Analyses of cancer data for three ezetimibe trials.N Engl J Med. 2008; 359 ([Epub 2008 Sep 2]): 1357-1366
- Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.Circulation. 2004; 110: 1291-1295
- Effect of statin treatment on aortic valve and coronary artery calcification.J Heart Valve Dis. 2007; 16: 378-386
- A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.N Engl J Med. 2005; 352: 2389-2397
- Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.J Am Coll Cardiol. 2007; 49: 554-561
- Aortic sclerosis, aortic stenosis and lipid-lowering therapy.Expert Rev Cardiovasc Ther. 2008; 6: 385-390
- Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering in the progression of aortic stenosis: the Aortic Stenosis Progression Observation: measuring Effects of Rosuvastatin (ASTRONOMER) trial.Am Heart J. 2007; 153: 925-931
- Overview of clinical trials on calcific aortic stenosis.Eur Heart J Suppl. 2008; 10: E31-E40
- The regulation of matrix metalloproteinases and their inhibitors.Int J Biochem Cell Biol. 2008; 40: 1362-1378
Drazen, JM, D’Agostino RB, Ware JH, Morrissey S, Curfman GD. Ezetimibe and cancer—an uncertain association. N Engl J Med 2008; published online at www.nejm.org (article 10.1056/NEJMe0807200) accessed November 24, 2008.
☆The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study is a double first: the first clinical outcomes trial for ezetimibe, and the first pre-specified clinical outcomes trial of statin therapy for patients with aortic stenosis (AS), in this case simvastatin in combination with ezetimibe [Rossebo AB, PedersenTR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970–73; Rossebo AB, PedersenTR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359, doi: 10.1056/NEJMoa0804602 (accessed November 24, 2008)].
☆☆SEAS enrolled 1873 elderly non-diabetic patients with mild to moderate AS, who had no definite indication for cholesterol-lowering therapy. It follows the ENHANCE study, in which patients with familial hypercholesterolaemia were treated with simvastatin alone or simvastatin plus ezetimibe [The ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431–43].